Atopic dermatitis (AD) is a common chronic inflammatory skin disorder characterized by cutaneous dryness, pruritus, scratching, and skin damage. 1 Although the etiology of AD remains largely unknown, it likely occurs as a result of multifactorial and heterogeneous conditions combined with interactions between the immune system and environmental factors. 2,3 International studies have demonstrated that the global prevalence of AD in school children was 7.0% in 6-to 7-year-olds and 5.7% in 13-to 14-year-olds. 4,5 In Tokyo, 15.9% children at 9 years old had current eczema form our birth cohort. 6 We also previously reported AD trajectory phenotypes from this birth cohort. 7 We identified four phenotypes, including never/infrequent (62.7%), early-onset (17.6%), late-onset (9.5%), and persistent (10.1%) phenotypes.Around 1% of young Japanese infants suffer from sleep disturbance due to eczema. 1 A Canadian study examined the impact of moderate-to-severe AD in children on quality of life and found that 85% felt their AD was not well-controlled, 27% had difficulty obtaining treatments for AD, and 52% of families reported impaired quality of life. 8 In Singapore, adolescents with AD reported low quality of life that affected physical activity. 9 In school children, chronic diseases such as AD are linked with emotions, physical activity, social activity, and families. It is crucial to identify best management of severe AD to achieve good quality of life in children and their families. 10 Topical corticosteroids (TCSs) are widely endorsed as a standard anti-inflammatory treatment drug for AD and are the first choice AD treatment for all ages. Previous studies have shown that proactive therapy using long-term, intermittent topical anti-inflammatory